480 related articles for article (PubMed ID: 22722998)
41. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
[TBL] [Abstract][Full Text] [Related]
42. VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4.
Tantsura LM; Pylypets OY; Tretiakov DV; Tantsura YO
Wiad Lek; 2023; 76(5 pt 1):1007-1013. PubMed ID: 37326083
[TBL] [Abstract][Full Text] [Related]
43. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.
Hilli J; Rane A; Lundgren S; Bertilsson L; Laine K
Fundam Clin Pharmacol; 2007 Aug; 21(4):379-86. PubMed ID: 17635176
[TBL] [Abstract][Full Text] [Related]
44. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW; Tshering G; Na-Bangchang K
J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
[TBL] [Abstract][Full Text] [Related]
45. Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry.
Falzoi M; Mossa A; Congeddu E; Saba L; Pani L
Pharmacogenomics; 2010 Apr; 11(4):559-71. PubMed ID: 20350138
[TBL] [Abstract][Full Text] [Related]
46. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
[TBL] [Abstract][Full Text] [Related]
47. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
Hiratsuka M; Takekuma Y; Endo N; Narahara K; Hamdy SI; Kishikawa Y; Matsuura M; Agatsuma Y; Inoue T; Mizugaki M
Eur J Clin Pharmacol; 2002 Sep; 58(6):417-21. PubMed ID: 12242601
[TBL] [Abstract][Full Text] [Related]
48. Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population.
Ota T; Kamada Y; Hayashida M; Iwao-Koizumi K; Murata S; Kinoshita K
Int J Med Sci; 2015; 12(1):78-82. PubMed ID: 25552922
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of five pharmacologically most important
Vidović S; Škrbić R; Stojiljković MP; Vidović V; Bećarević J; Stoisavljević-Šatara S; Maksimović N
Arh Hig Rada Toksikol; 2021 Jun; 72(3):129-134. PubMed ID: 34187105
[TBL] [Abstract][Full Text] [Related]
50. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
[TBL] [Abstract][Full Text] [Related]
51. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
52. Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
Ociepa-Zawal M; Rubiś B; Filas V; Breborowicz J; Trzeciak WH
Ginekol Pol; 2009 Nov; 80(11):819-23. PubMed ID: 20088394
[TBL] [Abstract][Full Text] [Related]
53. Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2.
Si D; Wang J; Zhang Y; Zhong D; Zhou H
Biopharm Drug Dispos; 2012 Sep; 33(6):342-5. PubMed ID: 22886551
[TBL] [Abstract][Full Text] [Related]
54. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
55. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
56. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
57. The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan.
Firasat S; Raza A; Khan AR; Abid A
Mol Biol Rep; 2023 May; 50(5):4017-4027. PubMed ID: 36849858
[TBL] [Abstract][Full Text] [Related]
58. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
59. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
60. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
